Information:
Fel:
ID
22396
Beskrivning
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01142583
Länk
https://clinicaltrials.gov/show/NCT01142583
Nyckelord
Versioner (1)
- 2017-06-01 2017-06-01 -
Uppladdad den
1 juni 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT01142583
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT01142583
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Sclerosis, Relapsing-Remitting NCT01142583
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
rrms or cis duration
Item
subjects with duration of rrms or cis ≤ 10 yr from onset of symptoms.
boolean
C0751967 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C2921627 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0449238 (UMLS CUI [1,2])
C2921627 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
age
Item
subjects aged between 18 and 55 years
boolean
C0001779 (UMLS CUI [1])
edss
Item
subjects with edss score of 0 to ≤ 4.0
boolean
C0451246 (UMLS CUI [1])
avonex®, betaseron®, copaxone®, rebif®
Item
subjects on consistent therapy with a single dmd (avonex®, betaseron®, copaxone®, rebif®) for at least 12 months.
boolean
C0594372 (UMLS CUI [1])
C0284968 (UMLS CUI [2])
C0528175 (UMLS CUI [3])
C0752980 (UMLS CUI [4])
C0284968 (UMLS CUI [2])
C0528175 (UMLS CUI [3])
C0752980 (UMLS CUI [4])
multiple sclerosis relapse, data available
Item
subjects whose relapse data over the last 12 months was available in the subject's chart
boolean
C0856120 (UMLS CUI [1,1])
C4035953 (UMLS CUI [1,2])
C4035953 (UMLS CUI [1,2])
edss, data available
Item
subjects whose edss data over the last 12 months was available in the subject's chart
boolean
C0451246 (UMLS CUI [1,1])
C4035953 (UMLS CUI [1,2])
C4035953 (UMLS CUI [1,2])
eligible to receive dmds
Item
subjects who were eligible to receive any of the 4 dmds
boolean
C1548635 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0242708 (UMLS CUI [1,3])
C1514756 (UMLS CUI [1,2])
C0242708 (UMLS CUI [1,3])
consecutive eligible
Item
consecutive subjects were screened until 10 eligible subjects were enrolled (to minimize any selection bias) - subject was therefore one of 10 consecutive eligible, consenting subjects
boolean
C1707491 (UMLS CUI [1,1])
C1548635 (UMLS CUI [1,2])
C1548635 (UMLS CUI [1,2])
informed consent
Item
subjects who had given written informed consent with the understanding that the subject could withdraw consent at any time without prejudice to future medical care
boolean
C0021430 (UMLS CUI [1])
reliable follow-up
Item
subject who was not expected to be followed reliably over the next 12 months
boolean
C1522577 (UMLS CUI [1,1])
C1321605 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,2])
study subject participation status
Item
subjects with concomitant participation in any other studies involving investigational or marketed products
boolean
C2348568 (UMLS CUI [1])
previously failed dmd therapy, switch between therapies
Item
subject wo had previously failed dmd therapy and/or switched between therapies
boolean
C0919875 (UMLS CUI [1,1])
C0242708 (UMLS CUI [1,2])
C3665894 (UMLS CUI [2])
C0242708 (UMLS CUI [1,2])
C3665894 (UMLS CUI [2])